Enrico Martin

181 Emerging therapeutic targets 78. Semenov a G , Stepanov a DS , Deyev SM, Chernof f J. Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis t ype 1. Biochimie. 2017;135:1-5. doi:10.1016/j.biochi.2017.01.001 79. Ghadimi MP, Young ED, Belousov R, et al. Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors. Clin Cancer Res. 2012;18(9):2545- 2557. doi:10.1158/1078-0432.CCR-11-2592 80. Ikuta K, Ota T, Zhuo L, et al. Antitumor effects of 4-methylumbelliferone, a hyaluronan synthesis inhibitor, on malignant peripheral nerve sheath tumor. Int J cancer. 2017;140(2):469-479. doi:10.1002/ijc.30460 81. Mashour GA, Drissel SN, Frahm S, et al. Differential modulation of malignant peripheral nerve sheath tumor growth by omega-3 and omega-6 fatty acids. Oncogene. 2005;24(14):2367-2374. doi:10.1038/sj.onc.1208425 82. Wang W, Lin W, Hong B, et al. Effect of triptolide on malignant peripheral nerve sheath tumours in vitro and in vivo. J Int Med Res. 2012;40(6):2284-2294. doi:10.1177/030006051204000626 83. Zewdu A, Lopez G, Braggio D, et al. Verticillin A Inhibits Leiomyosarcoma and Malignant Peripheral Ner ve Sheath Tumor Growth via Induction of Apoptosis. Clin Exp Pharmacol. 2016;6(6). doi:10.4172/2161-1459.1000221 84. van der Graaf WTA, Blay J-Y, Chawla SP, et al. Pazopanib for metastatic soft- tissue sarcoma (PALETTE): a randomised, double-blind, placebo - controlled phase 3 trial. Lancet (London, England). 2012;379(9829):1879-1886. doi:10.1016/ S0140-6736(12)60651-5 85. Simanshu DK, Nissley D V, McCormick F. RAS Proteins and Their Regulators in Human Disease. Cell. 2017;170(1):17-33. doi:10.1016/j.cell.2017.06.009 86. Kobayashi D, Hirayama M, Komohara Y, et al. Translationally controlled tumor protein is a novel biological target for neurofibromatosis type 1-associated tumors. J Biol Chem. 2014;289(38):26314- 26326. doi:10.1074/jbc.M114.568253 87. Nissan MH, Rosen N, Solit DB. ERK pathway inhibitors: how low should we go? Cancer Discov. 2013;3(7):719-721. doi:10.1158 /2159-8290.CD -13-0245 88. Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014;2(4):295-300. doi:10.1158/2326- 6066.CIR-14-0015 89. Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14(8):559-567. doi:10.1038/nrc3770 90. Ferrari A, Miceli R, Rey A, et al. Non- metastatic unresected paediatric non- rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. Eur J Cancer. 2011;47(5):724-731. doi:10.1016/j. ejca.2010.11.013 91. Li H, Velasco-Miguel S, Vass WC, Parada LF, DeClue JE. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res. 2002;62(15):4507-4513. 92. Mak IWY, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res. 2014;6(2):114-118. 93. Hooijmans CR, de Vries RBM, Ritskes- Hoitinga M, et al. Facilitating healthcare decisions by assessing the certainty in the evidence from preclinical animal studies. PLoS One. 2018;13(1):e0187271. doi:10.1371/journal.pone.0187271 7